Atanasio
Pandiella Alonso
Hospital Clínico San Carlos de Madrid
Madrid, EspañaHospital Clínico San Carlos de Madrid -ko ikertzaileekin lankidetzan egindako argitalpenak (45)
2024
-
T-reg transcriptomic signatures identify response to check-point inhibitors
Scientific Reports, Vol. 14, Núm. 1
-
Trastuzumab deruxtecan in breast cancer
Critical Reviews in Oncology/Hematology, Vol. 198
2023
-
Considerations for the clinical development of immuno-oncology agents in cancer
Frontiers in immunology, Vol. 14, pp. 1229575
2022
-
Antitumoral Activity of a CDK9 PROTAC Compound in HER2-Positive Breast Cancer
International Journal of Molecular Sciences, Vol. 23, Núm. 10
-
Enhanced Antitumoral Activity of Encapsulated BET Inhibitors When Combined with PARP Inhibitors for the Treatment of Triple-Negative Breast and Ovarian Cancers
Cancers, Vol. 14, Núm. 18
-
Genomic mapping of copy number variations influencing immune response in breast cancer
Frontiers in Oncology, Vol. 12
-
HER3 in cancer: from the bench to the bedside
Journal of Experimental and Clinical Cancer Research, Vol. 41, Núm. 1
-
Novel adcs and strategies to overcome resistance to anti-her2 adcs
Cancers, Vol. 14, Núm. 1
-
Prognostic value of the immune target CEACAM6 in cancer: a meta-analysis
Therapeutic Advances in Medical Oncology, Vol. 14
-
Transcriptomic Mapping of Non-Small Cell Lung Cancer K-RAS p.G12C Mutated Tumors: Identification of Surfaceome Targets and Immunologic Correlates
Frontiers in Immunology, Vol. 12
2021
-
Altered proTGFα/cleaved TGFα ratios offer new therapeutic strategies in renal carcinoma
Journal of Experimental and Clinical Cancer Research, Vol. 40, Núm. 1
-
Generation of antibody‐drug conjugate resistant models
Cancers, Vol. 13, Núm. 18
-
Genomic correlates of dna damage in breast cancer subtypes
Cancers, Vol. 13, Núm. 9
-
Genomic mapping of splicing-related genes identify amplifications in lsm1, clns1a, and ilf2 in luminal breast cancer
Cancers, Vol. 13, Núm. 16
-
In silico transcriptomic mapping of integrins and immune activation in Basal-like and HER2+ breast cancer
Cellular Oncology, Vol. 44, Núm. 3, pp. 569-580
-
MZ1 co-operates with trastuzumab in HER2 positive breast cancer
Journal of Experimental and Clinical Cancer Research, Vol. 40, Núm. 1
-
Mapping of genomic vulnerabilities in the post-translational ubiquitination, sumoylation and neddylation machinery in breast cancer
Cancers, Vol. 13, Núm. 4, pp. 1-23
-
Modelling hypersensitivity to trastuzumab defines biomarkers of response in HER2 positive breast cancer
Journal of Experimental and Clinical Cancer Research, Vol. 40, Núm. 1
-
Transcriptomic Correlates of Immunologic Activation in Head and Neck and Cervical Cancer
Frontiers in Oncology, Vol. 11
-
Transcriptomic profiles of cd47 in breast tumors predict outcome and are associated with immune activation
International Journal of Molecular Sciences, Vol. 22, Núm. 8